Figure 7.

Fractionated anti-HER2-DOTA-PRIT with IA of 167 MBq led to 100% regression to palpable CRs (8/8) in mice with medium-sized xenografts at treatment initiation, with no recurrence at 85 d. (A) Tumor response curves for the four treatment arms presented as mean ± SEM. Black arrows indicate day of injection of ¹⁷⁷Lu-DOTA-Bn. (B) Survival analysis of fractionated treatment. Survival was defined as time to tumor doubling and included deaths from other causes. Median survival was 35.5 d for no treatment, 18 d for BsAb, 30 d for control IgG-DOTA-PRIT, and undefined (prefer > 80 d) for anti-HER2-DOTA-PRIT.